fluoxetine has been researched along with metoprolol in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Maxwell, D; Pirmohamed, M; Proudlove, C; Walley, T | 1 |
| Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
| Akarachkova, ES; Dlusskaia, IG; Striuk, RI; Tabeeva, GR; Veĭn, AM; Volkova, ZI | 1 |
| Bedner, M; Maccrehan, WA | 1 |
| Molden, E; Spigset, O | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Barceló, D; Kasprzyk-Hordern, B; López-Serna, R; Petrović, M | 1 |
| Eren Cevik, S; Guneysel, O; Tasyurek, T | 1 |
| Nacheva, PM; Velázquez, YF | 1 |
| Bahar, MA; Borgsteede, SD; Bos, JHJ; Hak, E; Wilffert, B | 1 |
| Bahar, MA; Bos, JHJ; Hak, E; Wang, Y; Wilffert, B | 1 |
| Bahar, MA; Borgsteede, SD; Hak, E; Kamp, J; Wilffert, B | 1 |
| Chen, B; Gao, N; Hu, G; Li, Y; Wang, R; Xu, T; Zhang, X | 1 |
| Gedde-Dahl, A; Molden, E; Spigset, O | 1 |
4 review(s) available for fluoxetine and metoprolol
| Article | Year |
|---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Interactions between metoprolol and antidepressants].
Topics: Adrenergic beta-1 Receptor Antagonists; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Metoprolol; Paroxetine; Risk Factors | 2011 |
The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
Topics: Cytochrome P-450 CYP2D6; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Paroxetine | 2018 |
26 other study(ies) available for fluoxetine and metoprolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Interaction of metoprolol and fluoxetine.
Topics: Angina Pectoris; Depressive Disorder; Drug Interactions; Fluoxetine; Humans; Male; Metoprolol; Middle Aged | 1993 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
[Clinical significance of adrenoreactivity in patients with some paroxysmal disorders (panic attacks and migraine)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Humans; Hypertension; Male; Metoprolol; Migraine Disorders; Panic Disorder; Parasympathetic Nervous System; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Sympathetic Nervous System | 2003 |
Reactions of the amine-containing drugs fluoxetine and metoprolol during chlorination and dechlorination processes used in wastewater treatment.
Topics: Chlorine; Chromatography, Liquid; Environmental Restoration and Remediation; Fluoxetine; Metoprolol; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Water Pollutants, Chemical | 2006 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Multi-residue enantiomeric analysis of pharmaceuticals and their active metabolites in the Guadalquivir River basin (South Spain) by chiral liquid chromatography coupled with tandem mass spectrometry.
Topics: Atenolol; Chromatography, Liquid; Environmental Monitoring; Fluoxetine; Metoprolol; Pharmaceutical Preparations; Propanolamines; Propranolol; Reproducibility of Results; Rivers; Sensitivity and Specificity; Spain; Stereoisomerism; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2013 |
Intralipid emulsion treatment as an antidote in lipophilic drug intoxications.
Topics: Adolescent; Adult; Alprazolam; Amitriptyline; Antidotes; Blood Pressure; Dibenzothiazepines; Drug Overdose; Fat Emulsions, Intravenous; Female; Fluoxetine; Glasgow Coma Scale; Heart Rate; Humans; Lamotrigine; Lipid Metabolism; Male; Metoprolol; Middle Aged; Nifedipine; Quetiapine Fumarate; Triazines; Young Adult | 2014 |
Biodegradability of fluoxetine, mefenamic acid, and metoprolol using different microbial consortiums.
Topics: Biodegradation, Environmental; Bioreactors; Fluoxetine; Heterotrophic Processes; Kinetics; Mefenamic Acid; Metoprolol; Microbial Consortia; Oxidation-Reduction; Sewage; Water Pollutants, Chemical | 2017 |
The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Topics: Aged; Anti-Arrhythmia Agents; Cytochrome P-450 CYP2D6; Drug Interactions; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2017 |
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
Topics: Aged; Aged, 80 and over; Citalopram; Cohort Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Mirtazapine; Netherlands; Paroxetine | 2018 |
Inhibitory effects of fluoxetine and duloxetine on the pharmacokinetics of metoprolol in vivo and in vitro.
Topics: Animals; Chromatography, Liquid; Cytochrome P-450 CYP2D6; Duloxetine Hydrochloride; Fluoxetine; Humans; Metoprolol; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2022 |
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Topics: Antidepressive Agents; Atenolol; Bisoprolol; Bupropion; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Fluoxetine; Humans; Metoprolol; Paroxetine; Retrospective Studies | 2022 |